Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Local elections across major U.S. cities have kicked off a wave of policy changes that could reshape development costs, rental income, and investment strategies heading into 2026. From NYC’s aggressive tenant‑protection agenda to Chicago’s sustainability push, Miami’s political uncertainty, and Boston’s steady zoning overhaul, the post‑election environment is redefining how real estate professionals, investors, and lenders should prepare for the year ahead.
Insurance carriers are rapidly rolling out AI-related exclusions that strip coverage from claims involving AI tools, automated decision‑making, or generative platforms like ChatGPT and Midjourney. With firms like Berkley and Hamilton introducing sweeping “absolute” and generative‑AI‑specific exclusions, professionals in real estate, mortgage, insurance, and finance now face new liability gaps. As AI becomes unavoidable in everyday work, understanding these exclusions is essential for protecting your career and staying compliant in a fast‑changing risk environment.
Proptech startup Venn has raised a $52 million Series B to unify the entire renting lifecycle into one intelligent platform, replacing over a dozen traditional systems and serving more than half a million tenants. As AI‑powered tools like Venn rapidly reshape property operations, real estate professionals — especially in fast‑moving markets like Florida — will need stronger education and tech‑savvy skills to stay competitive.
Florida’s Gulf Coast is undergoing a dramatic transformation as soaring insurance premiums, costly construction requirements, and the long shadow of Hurricane Ian force middle‑class families, workers, and longtime residents out of communities they once anchored. With premiums topping $5,700 a year — and many paying far more — Realtors warn of looming foreclosures, renters face steep increases, and entire neighborhoods are being rebuilt for wealthier newcomers. This mounting crisis is reshaping the state’s real estate landscape and leaving professionals scrambling to adapt.
Economic uncertainty, rapid tech advances and shifting population patterns are setting the stage for a pivotal year in commercial real estate. New findings from the Counselors of Real Estate, presented at NAR NXT, outline ten major forces reshaping strategy, investment and opportunity in 2026—from policy impacts and portfolio risk to AI adoption, capital flow changes, housing attainability and demographic shifts. This outlook offers clarity and caution for professionals across real estate, mortgage, finance and related fields.
Florida’s home insurance crisis is back in the spotlight as new reforms appear to be repeating decades‑old mistakes. Despite efforts to depopulate Citizens and attract private insurers, many of the companies taking over policies have ties to past insolvencies. Critics say weak oversight, generous ratings, and political influence are allowing unstable insurers to thrive while homeowners pay more for less protection. Experts warn that without transparent ratings, real accountability, and unified regulation, Florida’s insurance market will remain vulnerable—putting property values, lending, and the broader real estate industry at risk.
